Qiagen N.V. (NYSE:QGEN) Q3 2022 Results Conference Call November 8, 2022 9:00 AM ET
Company Participants
John Gilardi – VP, Corporate Communications & IR
Thierry Bernard – CEO
Roland Sackers – CFO
Conference Call Participants
Odysseas Manesiotis – Berenberg
Casey Woodring – JPMorgan
Derik De Bruin – Bank of America
Falko Friedrichs – Deutsche Bank
Hugo Solvet – BNP Paribas
Ed Ridley-Day – Redburn
Operator
Ladies and gentlemen, thank you for standing by. I am Perry, your PGI call operator. Welcome, and thank you for joining QIAGEN’s Q3 2022 Earnings Conference Call Webcast. At this time, all participants are in a listen-only mode. Please be advised that this call is being recorded at QIAGEN’s request and will be made available on their Internet site. The prepared remarks will be followed by a question-and-answer session. [Operator Instructions]
At this time, I’d like to introduce your host, John Gilardi, Vice President, Head of Corporate Communications and Investor Relations at QIAGEN. Please go ahead, sir.
John Gilardi
Thank you, operator, and welcome to our call. The speakers today are Thierry Bernard, our Chief Executive Officer; and Roland Sackers, our Chief Financial Officer. Also joining us is Phoebe Loh from the Investor Relations team.
Please note that this call is being webcast live and will be archived on the Investors section of our website at www.qiagen.com.
Today, we’ll first have some remarks from Thierry Bernard and Roland and then move into the Q&A session. A presentation with details on our performance is available in the IR section of our website, along with the quarterly release.
We will not be showing the slides during this call. Before we begin, let me cover as usual, our safe harbor statement. This conference call discussion and responses to your questions reflect the views of management as of today, November 8, 2022. We will be making statements and providing responses to your questions that state our intentions, beliefs, expectations or predictions of the future. These constitute forward-looking statements for the purpose of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995.
These statements involve risks and uncertainties that could cause actual results to differ materially from those projected. QIAGEN disclaims any intentions or obligations to revise any forward-looking statements. For more information, please refer to our filings with the U.S. Securities and Exchange Commission, which are also available on our website.
We will also be referring today to certain financial measures not prepared in accordance with generally accepted accounting principles or GAAP. All references to EPS refer to diluted EPS or earnings per share. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures is available in our press release and the presentation. And again, these are both available on our website. I would like to now turn over the call to Thierry.
Thierry Bernard
Thank you, John, and good morning, good afternoon. Welcome to our conference call today, and thank you to everyone for joining. We are very pleased to report a strong performance in the third quarter of 2022. We indeed saw solid ongoing market trends with broad-based demand for both our molecular research and clinical diagnostic solutions across the business.
So let me get right to the top messages for today. First of all, we again exceeded our quarterly outlook for net sales growth and adjusted EPS. This was driven by the top performance in our non-COVID portfolio and also higher-than-expected sales from product used in COVID testing.
Net sales for the third quarter of ’22 were $533 million at CER and exceeded our outlook for $510 million. These results were largely unchanged from sales of $535 million in the third quarter of 2021, a period of high COVID-testing demand.
Our non-COVID product group delivered 18% CER sales growth over the third quarter 2021 and represented more than 80% of our total sales. Adjusted diluted earnings per share were $0.55 CER and above the outlook for at least $0.48. Those results demonstrate that our portfolios are performing very well.
In fact, this is the seventh consecutive quarter of double-digit CER growth in our non-COVID portfolio. This clearly underlines the strength of our business and the execution mindset across QIAGEN. Second key message, our teams have been delivering on key goals as we advance our five pillars of growth.
The performance for the nine months of 2022 underscore the strength and ability of QIAGEN in a very dynamic micro environment. I am definitely very proud of our teams. They have done an outstanding job this year remaining proactive and staying focused on executing our five pillars of growth strategy.
This is creating a very solid foundation for sustainable growth in the future. All of our five pillars of growth are on track to achieve and some are even likely to exceed significantly the sales goals we set for 2022. Our Sample Technologies product group is benefiting from a new wave of instrument upgrades.
This is helping QIAGEN to leverage our leading position in sample prep the first step in any molecular biology lab. We are driving consumables growth in non-COVID application, which is the larger portion of this business and by far. Remember, that DNA kits and nonviral related RNA prep make up more than 70% of sales in this group with COVID relevant viral RNA kits making up about $150 million of sales in 2019.
The QuantiFERON TB franchise for tuberculosis testing is performing very well as well, with year-to-date growth well above our target for more than $310 million. The demand for TB testing is on the rise. As noted in a recent report by the WHO that TB deaths and disease prevalence rose significantly during the COVID-19 pandemic.
For our integrated clinical PCR testing platform, NeuMoDx, two new tests were launched for use in areas such as transplant diagnostics. This brings the CE-IVD menu now to 16 tests on NeuMoDx, one of the largest available from any competitor. We are tracking well on system placement and seeing encouraging indicators on the transition from COVID to non-COVID utilization.
For QIAstat diagnostic, our offering for syndromic testing, the QIAGEN teams have responded to the monkeypox outbreak with the rapid development of the QIAstat-Dx viral vehicular panel. Placements are continuing to grow worldwide, and it is worth noting that more than 50% of sales for QIAstat are now for non-COVID application.
In terms of QIAcuity, our offering for digital PCR, we recently launched 13 new biopharma assays. This is an extremely important step in our entry into the biopharma area of the market where we see as an important customer segment involving pharma companies around the world, and it creates a strong base for future growth in 2023.
So as you can see, we are making good progress in our five pillars of growth. This fits very well into the overall strategy to maximize the value of our portfolio through our ability to address a broad range of customers in the continuum of life science to molecular diagnostics. Third key takeaway message for today.
We have increased our outlook for the full year 2022 based on another quarter of solid results. We are now expecting sales of about $2.25 billion for the full year 2022 with a reaffirmation of the goal for double-digit CER growth in our non-COVID portfolio.
As for EPS, we are now expecting about $2.40 CER for adjusted EPS, and this is up from our prior outlook for at least $2.30 CER. As always, we will stand ready to support the needs for COVID-19 testing and surveillance. And this also goes for other public health emergencies like we are seeing for monkeypox.
As for COVID trends, testing volumes have dropped significantly in most countries around the world. We are continuing to take a very conservative view of demand trends for COVID. But as we have said before, QIAGEN remains relevant for COVID testing, but we are not dependent on those sales.
Indeed, we continue to believe it was the very right decision to decouple our performance from COVID trends, and QIAGEN was in fact, among the first, if not the first, to do so. But our overriding focus remains on advancing our strategy based on our non-COVID portfolio while continuing, of course, to have our eyes open to the changing macro environment. Roland will be providing more details on the outlook later on this call.
For now, let me hand over to him for the financial update on the quarter.
Roland Sackers
Thank you, Thierry. Hello, and thank you from me as well for joining this call. Let me first start with a review of our results, and then I will come back later to discuss the outlook. In terms of net sales, at actual rates, they declined 7% in the third quarter on a year-over-year basis to USD500 million.
This was due to about six points of currency headwinds in light of the strong U.S. dollar against the euro and other currencies such as the yen. The sales result at constant exchange rates were USD533 million and ahead of the outlook for at least $510 million CER. We had a much better-than-expected performance in our non-COVID product groups with these sales up 18% CER.
The COVID product group sales were also better than expected. Even so, sales were down 43% CER over the year ago period. Sales of consumables and related revenues and also instruments were unchanged at constant exchange rates. Excluding the COVID-19 headwinds, sales for consumers and related revenues were up 17% CER, while instrument sales rose at a faster pace, about 20% CER.
In terms of sales among the four product groups, let’s start with Sample Technologies, which represents about 1/3 of total sales. Here, we saw solid double-digit CER growth in the non-COVID portfolio that represented 75% of sales in the third quarter of ’22.
However, the significant decline in COVID-19 testing demand led to the overall decline of about 2% at constant exchange rates over the year ago period. Diagnostic Solutions is our second product group, and this represented about 30% of sales. The key driver behind the growth in this group was a QuantiFERON franchise. Sales for the QuantiFERON TB test rose 14% CER in the third quarter on double-digit gains in all regions.
Take into account that sales for the first nine months of ’22 were $256 million at constant exchange rates. We are clearly set to exceed the full year target for over $310 million CER. In fact, we have now seen seven consecutive quarters of double-digit CER growth for QuantiFERON. The sales trends for the QIAstat and NeuMoDx clinical PCR testing system continued to align with our full year expectations.
In terms of QIAstat-Dx, we are seeing increasing demand and new customer interest following the launch earlier this year of the new CE-IVD meningitis panel. The addition of this panel has established a strategic critical mass in terms of menu that is necessary for adoption by many customers in this region.
In the PCR Nucleic acid amplification product group sales declined 5% CER in the third quarter. We saw a strong contrast here with significant double-digit CER growth in the non-COVID product group against a likewise significant double-digit CER decline in the COVID product groups. The Genomics NGS product group, which represents about 10% of total sales delivered sales growth of 6% at constant exchange rates as COVID related revenues continued to be soft.
Moving on to sales on a geographic basis. The Europe, Middle East, Africa region led with 3% growth at constant exchange rates for the third quarter. Among the top-performing countries where France, Germany, the Netherlands and the United Kingdom, driven by sales in non-COVID product groups.
In the Americas, non-COVID product group sales growth at a robust double-digit CER rate especially due to QuantiFERON and expansion of the QIAcuity franchise. This more than offset the significant decline in COVID sales that were seen across all areas of the COVID portfolio.
In the Asia Pacific, Japan region, sales at constant exchange rates were down 9% from the third quarter of ’21. In this region, we saw lower sales in a number of countries that had COVID-19 sales in the year ago period, such as Thailand, the Philippines and Indonesia.
This weighted on the overall performance and overshadowed double-digit CER growth in Australia and India. Sales in China declined about 3% CER in the third quarter but have risen at a mid-single-digit CER on a year-to-date basis. We continue to see good underlying trends but are closely monitoring the situation as the pandemic evolves. Moving down to income statement. The adjusted operating income margin came in at 28.7% of sales.
This was mainly due to our decision to accelerate investments into the business in light of the higher sales trends. This margin compares to 30.8% in the third quarter of ’21, which was clearly a period with exceptional sales growth for COVID products. Turning to the components.
The adjusted gross margin rose by one percentage point to 67.6% of sales in the year-ago period. This included favorable margin developments for QIAstat-Dx due to higher utilization and improvements in consumables’ production as well as contributions from product mix due to the Sample Technologies and Genomics NGS product groups.
R&D investments rose to 9.8% of sales in the third quarter from 9% in the year-ago period as we are accelerating these investments during the second half of ’22. Sales and marketing expenses also rose in the third quarter of ’22, rising about 1.8 percentage points to 22.9% of sales from the same period in ’21.
As mentioned, we have stepped up investments into the five pillars of growth in light of the strong results in ’22. And like others, we are also facing higher freight costs and also higher commissions in line with the strong sales performance. In terms of general and administrative expenses, this rose about one percentage point to 6.2% of sales.
This is mainly due to investments into IT systems and cybersecurity. Adjusted EPS for the third quarter was $0.55 at constant exchange rates and again, above our outlook for at least $0.48. Results at actual rates were $0.53 due to the strong currency headwinds. The adjusted tax rate was 18% at the high end of the range we had set for about 17% to 18%.
We continue to expect a full year rate of about 18% to 19%. Turning to cash flow. We saw strong trends in the third quarter of ’22 and continuing the trends from earlier the year in terms of both operating cash flow and free cash flow. Thanks to the solid business expansion, operating cash flow rose 34% to USD591 million over the first nine months of ’21.
Free cash flow rose at an even faster 67% pace in the first nine months of ’22 over the year-ago period. This was due to lower purchases of property planted equipment in ’22, following the completion of important investments during ’22 and ’21 to expand production capacity.
These investments fell to 5.2% of sales in the ’22 period from 8.3% in the first nine months of ’21. In terms of our balance sheet, our total consolidated net debt stood at USD402 million at September 30, ’22 compared to USD876 million at December 31, ’21. This has decreased due to the cash, cash equivalents and short-term investments held at the end of the third quarter.
Based on this, our leverage ratio stood at 0.4 net times — net debt to adjusted EBITDA at the end of the third quarter. For your information, during the month of October, we have used USD480 million of our cash balance to repay a number of debt maturities from the U.S. private placement issued in 2012 and the short-run issued in 2017.
We are reviewing different ways to put the balance sheet to work and continue to take a disciplined view on capital deployment. This policy has been in place for a decade and has served us well. It involves both targeted bolt-on M&A deals along with share repurchase programs.
With that, I would like now to hand back to Thierry.
Thierry Bernard
Thank you, Roland. And please now allow me to go over some of the key updates our teams have made in the progress of advancing our five pillars of growth within our overall growth strategy. Starting, first of all, in Sample Tech. Here, we are working in tandem to update our instrument and automation system in combination with new kits to further develop application in key areas.
Just as an example, in the third quarter, we released a new workflow leveraging the new easy-to-connect instrument with the QIAcuity digital PCR instruments for liquid biopsy applications. This workflow combines the key features of these two platforms, the very high-quality sample prep with easy tool and QIAcuity’s high sensitivity in order to handle the demands of high-volume liquid biopsy samples.
This unique power of two offers optimize detection and quantification for successful biomarker profiling. This also builds on QIAGEN’s comprehensive liquid biopsy portfolio. In fact, QIAGEN is one of the only providers able to master all liquid biopsy analyzes. Those include circulating DNA, circulating tumor cells and exosomes.
Our teams have also expanded the range of kits for the QIAxcel Connect instrument that is used for quality control analysis. Those new kits make QIAxcel even more attractive for analysis of DNA and RNA in next-generation sequencing application. Our second growth pillar involves QuantiFERON, the modern gold standard for detection of latent tuberculosis.
We remain extremely committed to bringing TB testing solution to as many countries around the world as possible. As for QIAreach, the test version launched earlier this year for high burden low-income countries. Our partner, Illumina has recently entered insolvency proceedings. We still are working on new options for this product and are also very much open to new solutions to improve TB testing in emerging countries.
But keep in mind that the QIAreach sales expectation have no impact on the midterm QuantiFERON growth plans. As regard to QIAstat diagnostic, I mentioned the new QIAstat panel for viral vesicular detection. This is a panel for detection of monkeypox and all the viral pathogens for research and epidiomological surveillance.
These panels confirm once again our ability to remain extremely agile and responsive to public health needs. It is another example of the flexibility we have with the QIAstat diagnostic system and the growing use for syndromic testing.
During 2022, we have added the meningitis panel to the CE-IVD menu in Europe, and we are now able to offer along with the respiratory and GI panels. As you know, we already offered a respiratory panel in the U.S. and have submitted the gastrointestinal panel to the FDA.
We are expecting a decision during 2023. The meningitis is planned to be submitted to the U.S. approval in 2023 as well. In terms of placement, we are seeing solid trends for QIAstat diagnostic modules and, in particular, a very good interest among European customers for the higher throughput QIAstat-Dx Rise version.
So even after the demand during COVID, we continue to see very encouraging placement trends. For NeuMoDx, we launched two new CE-IVD tests during the third quarter, a test for the Epstein-Barr virus (EBV) and the test for human Herpesvirus 6.
We can now offer 16 CE-IVD test on the NeuMoDx system, and this addition strengthens our offering for transplant patients. Another achievement was the certification of the NeuMoDx platform under the new European Union In Vitro Diagnostic Medical Devices regulation. This replaced the previous IVD rules and is impacting companies across the health care sector with additional R&D and regulatory costs.
And in terms of placement, we are also continuing to see robust demand around the world, especially given the ability of labs to use NeuMoDx to automate the processing of LDT’s laboratory developments. In the PCR and Nucleic acid amplification group, the new biopharma assets for QIAcuity are being well received in the market. QIAcuity systems are increasingly adopted to enhance drug safety and efficacy in order to leverage the higher level of sensitivity and accuracy offered by digital PCR technology.
This new group of QIAcuity assays are designed to address key application areas, especially for sales and gene therapy topics. The eight-plate QIAcuity platform is proving to be popular in those customers’ application as well since it delivers high throughput capacity not offered by other platforms.
Finally, in genomics and NGS, a new group of QIAseq panels has been launched to expand our offering, involving Universal NGS solution. This portfolio can be used to prepare and analyze samples on any sequencing system. The new panels are designed for rapid processing to cut library prep time in half and to enable ultrasensitive variance analysis.
Those new kits are confirmation that we are continuing to launch innovative chemistry to help customers optimizing NGS workflows worldwide. As part of this strategy, we continue to partner with sequencing instrument provider to ensure access to our solution. At this point, let me hand it back over to Roland for more details on our new 2022 outlook.
Roland Sackers
Thank you, Thierry. Based on the better-than-expected results in the third quarter and also the solid outlook for the fourth quarter, we have increased our full year sales outlook to about USD2.25 billion at constant exchange rates. This is an increase from the prior outlook for at least USD2.2 billion and compares to $2.2 billion of sales in ’21.
In the first three quarters of ’22, we delivered 14% CER growth in our non-core product groups and expect double-digit CER growth to continue into the fourth quarter putting us on track to achieve our full year goal. We are maintaining our conservative view on COVID testing and for these sales in ’22 to be below the 21% level of USD704 million.
In the first three quarters of ’22, we had USD427 million of COVID product group sales at constant exchange rates. Our latest planning is for COVID product group sales to be about $500 million at constant exchange rates. Clearly, we are also able to absorb within our full year outlook the impact of losing about 1% of annual sales due to the Russian invasion of Ukraine and the suspension of our business in Russia.
In terms of profitability, we have upgraded our outlook for adjusted EPS to be about $2.40 at constant exchange rates. This is an increase of $0.10 from the prior outlook for at least $2.30, and this compares with our initial ’22 outlook for adjusted EPS of about $2.05 at CER. The progress in our business, however, is increasingly impacted by adverse currency movements against the U.S. dollar.
Based on exchange rates as of October 31, ’22, currency movements against the dollar are now expected to create an adverse impact of about six percentage points on net sales. The adverse headwinds are also expected to reduce adjusted EPS at actual rates by $0.09 to $0.10 per share.
At actual rates, this applies sales of about USD2.1 billion and adjusted EPS of about $2.30 to $2.31. For the fourth quarter, we have set an outlook for sales to reach at least USD520 million at constant exchange rates, that for adjusted diluted EPS of at least $0.50 also at CER.
It takes into consideration the acceleration of investments in light of the strong performance and also our decision to make onetime payments to support QIAGEN employees in light of the current high inflation environment. We expect currency headwinds in the fourth quarter to have an adverse impact of about seven percentage points on sales and about $0.03 on adjusted EPS.
At actual rates, this implies sales of at least USD483 million and adjusted EPS of at least $0.47. I would like to now hand back to Thierry.
Thierry Bernard
Thank you, Roland, and thank you all for your attention. I think it’s time to go to a quick recap of our key messages before we move into the Q&A session. First, our results exceeded the outlook for the third quarter of 2022, driven by the 18% CER growth from our non-COVID product group and adjusted earnings per share of $0.55 CER well above the previous outlook of $0.48 CER.
Second, our teams remain fully engaged and continue to execute on our five pillars of growth strategy. And lastly, we have increased our 2022 full year outlook to reflect the better-than-expected sales and profitability in the third quarter. With that, we are reaffirming our commitment for double-digit growth of our non-COVID portfolio in 2022.
And as we look into 2023, based on what we see today, there is no reason why QIAGEN non-COVID product group should not continue at a double-digit CER growth rate in the new year as well.
I now would like to hand back to John and the operator for the Q&A session. Thank you all.
Question-and-Answer Session
Operator
[Operator Instructions] And our first question comes from Odysseas Manesiotis of Berenberg. Odysseas, please go ahead.
Odysseas Manesiotis
I’ve got two to three. First of all, I think you’ve been communicating a high single-digit to low double-digit growth in the non-COVID business potentially rolling on to next year. I wanted to ask the dynamics here between different divisions, particularly your growth pillars.
Would it be fair to assume midterm guidance growth, for example, double-digit growth for all growth pillars, except sample prefer next year? And secondly, on QIAstat, could you please I’m sure give us a confirmation of whether you’re still planning to launch the GI, meningitis and BCID panels in the U.S. for next year? Is this plan still on track?
Thierry Bernard
Thanks a lot, Odysseas. And for your first question, first on the, let’s say, midterm growth profile, so first of all, I’d like to highlight that we are not in the midterm, basically, guidelines. But as we said, based on the results that we are seeing today, based on our knowledge of the current environment, we see no reason indeed to see the non-COVID portfolio of QIAGEN not growing at double digit next year.
And if you want to focus on the five pillars, you are perfectly right. We see indeed QuantiFERON, QIAstat, NeuMoDx and QIAcuity continuing to grow at double digits. And as we said back in December 2020 in the QIAGEN Investor Day, we see our Sample Tech portfolio growing at mid-single digit indeed.
Now to the question on QIAstat, we have submitted DI for the U.S. approval. We expect, as I said before, an approval in 2023. Our plan is to submit the meningitis panel before the end of 2023. You also mentioned BCID, the BCID panel is not planned to be submitted in 2023. We want first to launch it in Europe. And then we will submit it in the U.S., but probably around the end of 2024.
John Gilardi
Operator, let’s move to the next question.
Operator
The next question comes from Casey Woodring of JPMorgan. Casey, please go ahead.
Casey Woodring
How should we think about the setup for 2023? Is the strong performance this year creating a tough non-COVID comp for next year? And then how should we think about the moving parts to gross margins next year as well with COVID, actually, revenue rolling off? And higher input costs and you’re balancing that out with the pricing. Can we expect gross margin expansion next year?
Thierry Bernard
I think we can take this, Roland and I. And I will ask Roland to chime in also on the gross margin. On the overall perspective, you asking probably that we have raised our guidance for COVID sales 2022 to around $500 million.
We continue to take a conservative approach on COVID evolution post 2022. We do not want to have our P&L depending on COVID volatility. And therefore, we expect basically those COVID sales 2022 — or ’23, I’m sorry, to decrease by more than 50%. This is our current assumption. This being said, our focus is on the non-COVID part of our portfolio.
And this, I repeat, based on what we have in hands today, we see no reason to have that non-COVID part of our portfolio growing at less than double digit for 2023. This being said, I would like to invite Roland to comment on the gross margin.
Roland Sackers
Yes. And as Thierry said before, we are clearly not in the guidance call right now for ’23. Nevertheless, I think what we are willing to reconfirm today is as Thierry talked about the revenue side. I think it’s also fair to say that the comments we made before on profitability are still very valid, which means, as you know, we always said that we want to be post-COVID stronger than we were pre-COVID, and you recall that pre-COVID we had an adjusted EBITDA margin of 27% plus X percent.
And we clearly do believe that also now moving into at ’23, we should be nicely above the 27%, right? Look, exactly is clearly also a question of certain things are moving from price increases to inflations. Overall, I would say the trend right now over the last couple of weeks were rather positive. So I do think we will move quite strong into the year ’23.
Operator
Our next question comes from Derik De Bruin of Bank of America. Derik, please go ahead.
Derik De Bruin
Can you talk a little bit about your genomics portfolio, specifically the demand that you’re seeing for sample prep and some of your panels and such? There’s obviously been a little bit of choppiness in the genomics market to be sort of seeing some results. So what you’re feeling there. And just your overall thoughts on how you’re viewing Europe and demand there going into the end of the year and in 203?
Thierry Bernard
Derik, can you repeat the second part of your question on Europe, please? I didn’t get that. Your voice was a bit muted. I apologize.
Derik De Bruin
Sorry. Yes. Sorry about that. No, just basically, what’s your expectations are for Europe as you look into the fourth quarter and into ’23. It’s just sort of like — do you expect to see that region softening and any headwinds there?
Thierry Bernard
Okay. So first, addressing the genomics. I — obviously, we follow carefully the evolution of the market. We follow obviously the reporting and publication of our competitors. I’d like to remind our audience today that QIAGEN since 2019 has chosen a completely platform-agnostic strategy.
Our chemistry is universal and our bioinformatics is universal and can be used on any different kind of platforms, be they Illumina, Thermo, Element, BDI or [indiscernible]. So I believe that not being involved into the platform sales, we are less exposed than potentially some other companies because of the market evolution at the moment. Now our universal NGS consumables, saw a single-digit growth against high sales in the third quarter of 2021.
And if you remember, we have this kind of small base effect because last year, in Q3 of ’21 there was a higher consumption of normal UNGS, customers were coming back. And at the same time, we had government still investing in sequencing of positive PCR for COVID to try to detect the evolution of the mutation of the virus. And so this is why we are in Q3 in that single-digit growth.
That being said, overall, I do not see a reason to go lower than double-digit growth for our UNGS portfolio as we did, by the way, pre-COVID. Second, your question to Europe, once again, we are not in a guidance call or in the 2020 call. You have seen that Europe, Middle East and Africa had kind of leading growth in Q3.
We have strong basis there. We have direct subsidiaries in most of the countries. We are obviously extremely, extremely attentive to the economic situation. Europe is part of the geography where we have — and we are passing a second set of price increase in July of this year.
We will now pass the third set of price increase starting January 2023. So this is what I can say at the moment, very attentive to the economic environment at the same time, very solid in our organization in this geographic area.
Operator
The next question comes from Falko Friedrichs of Deutsche Bank.
Falko Friedrichs
Two questions, please. Firstly, can you quantify the price increases that you pushed through this year for us? And what do you expect for next year on top of the ones you passed through this year? And then secondly, on digital PCR, where you showed a pretty good performance again. How do you see that market developing going forward now? And do you see Roche new device as a bit of a risk to your device?
Thierry Bernard
Thank you so much, Falko. And very quickly, and Roland, obviously, if you want to chime in on the price increase, obviously, feel free. So we always explained that we have a normal established policy of a yearly price increase that happens normally in January of every year between December of the previous year and January. This year, starting July, we have decided in light of inflation on a selected number of countries to pass a second price increase.
And we disclosed in our Q2 results that we were targeting overall lease price, a 6% to 7% price increase, for that second wave. Now obviously, once this objective is set, we negotiate customer by customers to see what we can obviously achieve net-net, and we are still basically living through that at the moment.
We explained to you as well that when we say 6% to 7% price increase, you should not consider on the total base of customers. Why? First of all, because as we said, it’s on selected geographies obviously, in our main markets, but also because we are in a contract, pre-annual contract with some customers, and therefore, in those pre-annual contracts, we have a guaranteed volume that normally price are already locked for one, two or three years.
Nonetheless, as I disclosed also in our Q2 call, I said that given the specificities of higher inflation this year, we are also visiting those pre-annual customers to try to negotiate something. So it’s too early to give you a definitive impact. What I can tell you is that, obviously, we have a net-net positive impact of those price increases.
For next year, we are working on the increase. We take into account, obviously, what we have passed in January of ’22, what we have passed in July, and then we will determine the best number possible together with our customers. Roland, would you like to add something on the price increase, perhaps?
Roland Sackers
No. I think it was pretty well answered. Thank you.
Thierry Bernard
On the digital PCR, we continue to see that market growing. You remember, Falko, that we said 3% [indiscernible] at this moment, this is probably a $350 million to $400 million market. But the market we need to consider the total accessible market is rather the total Q-PCR market, which is above $3 billion. So we see it as a very growing market, dynamic market, especially for QIAGEN because we believe that with QIAcuity, we have a highly differentiated solution.
I remind you, three different workflows, three completely integrated boxes, whereas with competition at this moment, you have to piecemeal basically a workflow to get your final digital PCR result. And this is the case of Roche. We obviously observed the entrance of Roche in that market. It proves, once again, that this market is dynamic.
We believe that Roche will help us growing the interest of customers in digital PCR. But I must say, they come with an offer which is not fully integrated, which is made of two components. So I never criticized competition, but I still believe that given its specificities, QIAcuity is well placed to take a leading position on this market.
Operator
The next question comes from Hugo Solvet with BNP Paribas.
Hugo Solvet
I have two on supply chain. Some of your peers have been impacted by shortages of electronics and chips mainly in life science instrumentation. What is the situation for QIAGEN at the moment as it does not seem to have an impact on instrument for life science customers? And second, on NeuMoDx, can you update us on the recent progresses that have been made on the broadening of the U.S. menu?
Thierry Bernard
Very good. Thank you, Hugo. On the supply — and I think Roland also discussed that extensively during our Q2. First of all, we highlight that as unlike other companies, we have been prepared of tight supply situation by COVID. You remember that at the beginning of COVID in 2020 and in 2021, they were extremely difficult supply situation in some key components such as biologics or plastic.
What does it mean? It means that our company, our supply and purchasing team is extremely prepared and extremely on the ball, I would say, for more than two years now on those supply issues. We have taken some very specific measures, such as not hesitating, for example, to take a purchasing commitment with suppliers of around one year because we don’t want to put our customers in our difficult situation. So I do not want to say that there is absolutely no pressure on our supply chain.
Of course, there are but I think they are managed at QIAGEN because we have taken proactive measures. And it’s very also interesting for us to see that our backorder, our normal backorder level, at QIAGEN is back to the level that we had at the pre-COVID situation, and this is very encouraging. Roland, a word on supply chain, perhaps?
Roland Sackers
Yes. Overall, I would say the benefit we had is clearly that because of the volatility we have seen in some of our markets, COVID also in some of the growth opportunities we have in the non-COVID side, we decided quite early even in — as early as in 2020 to increase our, more or less, inventory on semi-finished goods.
And I think that’s very helpful right now. Of course, in all fairness, most of the challenges companies see in this industry is also coming out of logistic challenges and with a relatively good inventory level, I think you can write that out a bit.
Thierry Bernard
Now we go moving to your second question, which is basically the status of the U.S. menu expansion for NeuMoDx. If you remember Hugo, we have talked several times since 2021 about the regulatory situation in the U.S. for NeuMoDx. First of all, I’d like to highlight that our midterm growth profile for this solution is not changing, and we still expect a double-digit growth profile for NeuMoDx worldwide.
Our first priority has been first to answer the global call for testing during the COVID pandemic. Let us remember that the development of single plex or the development of [4 plex] on NeuMoDx was absolutely not forecasted initially. The pandemic also started during the initial launch of the system.
And like you have seen with any new system on the market, there is always a period of work where we improve the stability of the system. And this basically was given a priority by QIAGEN and also led to delays in FDA handling submission. At the end of 2022, we are now back in a position to dedicate more resources more emphasis, more focus on developing the U.S. test menu in the coming years, and you will see more submission starting again in 2023.
Remember also for the U.S. that NeuMoDx benefit from one very unique capability, which is it’s still the only system able to run regulated assays and LDTs on the system at the same time in a random way. And this is unique, and this is why we can still continue to sell in the U.S., even if, obviously, we have less menu than in Europe for the moment.
Operator
The last question comes from Ed Ridley-Day of Redburn.
Ed Ridley-Day
[indiscernible] for your domestic clients, do you see any certain wage inflation and labor shortages? And to what extent do feel you’re positioned to help them with those challenges? And just a quick follow-up on China. If you could just you just remind us now at sort of current run rate, the percent of sales in China, and if you can give us any more color on what the sort of current trading environment is in China, that would be helpful.
Thierry Bernard
So Ed, I do apologize once again, I don’t know if it’s coming on my hand, but I didn’t understand the first part of your question. I heard words like inflation and wages. Perhaps you might want to repeat that one?
Roland Sackers
I think the question, Thierry, was on, more or less, what we are doing for our employees there and the — pipe in the [indiscernible].
Thierry Bernard
Do you want to take that one, Roland, before I move to China, perhaps?
Roland Sackers
Sure. No, let’s do that. No. And I think what I was trying to say in our prepared minute is that QIAGEN decided in countries where inflation has clearly a larger than average increase to help our employees with a onetime payments here in the fourth quarter. So it will overall affect roughly more than half of our employees. And that’s clearly something what we’re doing for this year.
We clearly also more in the situation for next year. We clearly expect also that salary increases in next year overall will be probably higher than what we have seen before because of, again, on the one hand side, we are having a good performance, but clearly also that inflation challenges are going to stay. So I think it’s one way to really taking out our ownership here and our responsibility towards employees very seriously.
Thierry Bernard
Thanks a lot, Roland. And moving to China, Ed. So clearly, ratio-wise, I would say, China, remember, it’s around 6% to 7% of our sales. So we don’t have the same kind of exposure than some of our peers. At the same time, I would highlight that I think organization-wise, we are quite well prepared to answer the challenges of the Chinese market.
You remember in the past, we mentioned localization, nationalization of some health care segment. Remember that we have a site in Shenzhen for local manufacturing and development and we have also a second brand in China. So obviously, we follow extremely carefully the very unpredictable situation with lockdown because it’s a very moving situation.
And so results wise, as we have said today, for the first nine months of 2022, our sales are up 4% CER over 2021 same period. But in Q3, we saw a sales decline of 3%. It was completely factored in our new guidance that we gave already in the Q2 call. We continue, obviously, to see opportunities in the China market. Let’s never forget that whatever the challenge is, it’s still the second market in the world from a size standpoint.
But compared to probably the pre-COVID period, we see those opportunities at a lower rate than before 2019.
John Gilardi
Okay. Thank you very much, Thierry. And with that, we want to end the call here. We appreciate your interest in QIAGEN. If you have any follow-up questions or topics to discuss, please reach out to Phoebe and me, and we’re available to help you out. Thank you very much.
Operator
Ladies and gentlemen, this concludes the conference call. Thank you for joining, and have a pleasant day. Goodbye.
Be the first to comment